Gsk (GSK) EPS (Basic) (2009 - 2026)

Gsk (GSK) has 18 years of EPS (Basic) data on file, last reported at $1.44 in Q3 2026.

• For the quarter ending Q3 2026, EPS (Basic) changed N/A year-over-year to $1.44; the trailing twelve-month figure through Sep 2026 stood at $4.9 (changed N/A YoY), and the FY2025 full-year result was $3.75, up 132.47% from the prior year.
• EPS (Basic) was $1.44 for Q3 2026 at Gsk, up from $0.29 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $6.37 in Q3 2022 to a low of -$0.04 in Q3 2024.
• A 5-year average of $1.33 and a median of $1.01 in 2023 frame the typical range for EPS (Basic).
• Across the five-year window, EPS (Basic) plunged 104.04% in 2024 and surged 3682.31% in 2025, its largest moves.
• Gsk's EPS (Basic) stood at $1.54 in 2022, then advanced by 24.01% to $1.91 in 2023, then slipped by 26.76% to $1.4 in 2024, then soared by 44.16% to $2.01 in 2025, then retreated by 28.52% to $1.44 in 2026.
• Per Business Quant data, the three most recent EPS (Basic) figures were $1.44 in Q3 2026, $0.29 in Q2 2026, and $1.16 in Q1 2026.